April 21, 2021 10:59 AM EDT
News Briefing

No­vo Nordisk to launch PhI­II obe­si­ty tri­al for oral semaglu­tide; Edi­Gene ex­tends Se­ries B with ad­di­tion­al $62M

Max Gelman

Senior Editor

On the heels of a high­ly suc­cess­ful tri­al for its block­buster di­a­betes drug semaglu­tide in obe­si­ty, No­vo Nordisk is prep­ping a Phase II­Ia study for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times